Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Pomalidomide
Immunosuppressant · Immunotherapy responsive malignancy
ImmunosuppressantImmunotherapy responsive malignancy
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- AtezolizumabSevereDatabaseDDInter
- AvelumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
Mechanism
Pomalidomide is structurally related to thalidomide. It exhibits immunomodulatory properties and direct anti-myeloma tumoricidal activity.
Indications
Treatment of relapsed and refractory multiple myeloma in patients who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and who have had disease progression during the last treatment (in combination with dexamethasone)MM who have received at least two prior therapies including lenalidomide (in combination with dexamethasone)AIDS-related Kaposi sarcoma
Dosing
- Adult
- BY MOUTH: 4 mg once daily for 21 consecutive days of repeated 28–day cycles; for doses of dexamethasone and dose adjustment due to side effects—consult product literature
Contraindications
- Cardiac disease
- Cardiac risk factors
- Hepatitis B infection (screening required before initiation due to reactivation risk)
- High tumour burden (risk of tumour lysis syndrome)
- Interstitial lung disease (discontinue if suspected)
- Peripheral neuropathy
- pregnancy
- females who may become pregnant
Side effects
Serious
- Hepatitis B reactivation
- Tumour lysis syndrome
- Interstitial lung disease
- Peripheral neuropathy
- Thromboembolism
Pregnancy & lactation
Pregnancy
X
Drug interactions
Atezolizumab
Severe
Database
Drug interaction classified as: others
Source: DDInter
Avelumab
Severe
Database
Drug interaction classified as: others
Source: DDInter
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Conestat Alfa
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Conjugated Estrogens
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Darbepoetin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Deferiprone
Severe
Database
Clinical effect not specified
Source: DDInter
Diethylstilbestrol
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Coeliac disease
OTHER · Gastroenterology · 2016
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Diabetic foot — clinical management
MOHFW · Endocrinology · 2021
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Other Immunosuppressant drugs
Ask House about Pomalidomide
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team